Integrating EHRs and Imaging in Cancer Trials

Discover how MONAI Multimodal integrates EHRs and imaging to enhance cancer trial operations with AI-driven insights for 2026.

Kevan Shah · · 8 min read

Cancer trials are entering a new era where data integration is as important as drug discovery. How MONAI Multimodal integrates EHRs and imaging for 2026 cancer trials is quickly becoming a defining question for research teams trying to operationalize multimodal AI—because the most valuable insights often sit at the intersection of radiology images, pathology slides, clinical notes, and structured EHR data.

Historically, oncology research has suffered from fragmented pipelines: imaging stored in PACS, pathology in slide systems, outcomes buried in EHRs, and trial metadata locked in spreadsheets. Today, platforms like MONAI Multimodal are designed to unify these sources into a consistent, reproducible ecosystem for medical AI research and clinical applications, integrating data types like CT, MRI, X-ray, ultrasound, and electronic health records (EHRs) into a single workflow foundation. (Source: https://developer.nvidia.com/blog/monai-integrates-advanced-agentic-architectures-to-establish-multimodal-medical-ai-ecosystem/)

This post breaks down what MONAI Multimodal is, what “agentic” multimodal medical AI really means in practice, and how these capabilities map directly onto the operational realities of 2026 cancer trials—from cohort discovery and eligibility checks to imaging endpoints and response assessment. We’ll also highlight practical ways teams can automate the “last mile” with workflow orchestration (including n8n workflows) and how an AI consulting partner can accelerate production-grade deployment.

How MONAI Multimodal integrates EHRs and imaging for 2026 cancer trials

MONAI Multimodal represents an evolution of the MONAI platform focused on integrating diverse healthcare data types—including imaging and EHRs—into a unified ecosystem for medical AI research and clinical applications. (Source: https://developer.nvidia.com/blog/monai-integrates-advanced-agentic-architectures-to-establish-multimodal-medical-ai-ecosystem/)

At the technical level, the platform is designed to handle two fundamental challenges that routinely stall cancer AI projects:

  1. Cross-modal alignment: linking imaging studies (e.g., baseline CT, follow-up MRI) with patient-level structured EHR fields (medications, labs, diagnoses) and unstructured notes.
  2. Reproducibility and scale: ensuring pipelines can be rerun across sites and time, with consistent preprocessing, model selection, and evaluation—critical for regulated clinical research.

In oncology trials, this is not a “nice to have.” It’s often the difference between a promising retrospective study and a deployable trial-grade pipeline.

What’s new: agentic architectures for multistep reasoning across images and clinical documentation

One of the most important technical details in the MONAI Multimodal approach is the use of advanced agentic AI architectures to enable multistep reasoning across both images and clinical documentation. (Source: https://developer.nvidia.com/blog/monai-integrates-advanced-agentic-architectures-to-establish-multimodal-medical-ai-ecosystem/)

Why “agentic” matters in real oncology workflows

Classic AI pipelines in medical imaging often look like this:

  • Input CT → segmentation model → numeric features → simple classifier/regressor → output

That can work for narrow tasks, but cancer trials require more:

  • Determine if a patient meets eligibility criteria (often dependent on labs, prior therapies, staging, comorbidities, and timing)
  • Identify and measure target lesions across timepoints (radiology)
  • Correlate imaging changes with treatment administrations and adverse events (EHR)
  • Produce an auditable narrative for review by clinicians and trial monitors

“Agentic” systems are built to chain steps—for example:

  1. Locate relevant EHR elements (structured + notes)
  2. Retrieve the correct imaging series and timepoints
  3. Run the appropriate imaging model (e.g., tumor segmentation)
  4. Compare longitudinal imaging measurements
  5. Summarize results with citations back to source documents and timestamps

This is the direction oncology trials are moving: less “single-model prediction,” more “end-to-end task execution” with traceable reasoning steps.

Specialized medical LLMs and VLMs: bridging radiology imaging and structured clinical data

MONAI Multimodal’s integration is enabled by specialized large language models (LLMs) and vision-language models (VLMs) designed specifically for medical applications, which simplify cross-modal data integration between radiology imaging and structured clinical data. (Source: https://developer.nvidia.com/blog/monai-integrates-advanced-agentic-architectures-to-establish-multimodal-medical-ai-ecosystem/)

How LLMs and VLMs actually help in trials

For 2026-era cancer trials, the hardest work is often not segmentation accuracy—it’s “data wrangling at clinical depth.” Here are concrete ways medical LLMs/VLMs contribute:

  • Clinical note understanding: Extracting prior lines of therapy, ECOG performance status, progression notes, contraindications, and symptom onset from oncologist narratives.
  • Protocol-to-EHR mapping: Turning inclusion/exclusion criteria into computable queries over structured labs and diagnoses and unstructured text.
  • Cross-modal retrieval: Finding the right imaging study based on clinical events (e.g., “CT chest/abdomen/pelvis performed within 28 days prior to Cycle 1 Day 1”).
  • Narrative generation with grounding: Producing trial-ready summaries (e.g., response assessments) that point back to lesion measurements and EHR evidence.

The key is that multimodal models don’t replace classic imaging models—they connect them to the broader clinical context required for trial operations.

Breaking down silos: consolidating radiology, pathology, notes, and EHRs into a reproducible framework

MONAI Multimodal consolidates radiology, pathology, clinical notes, and EHRs into a consistent, reproducible framework, breaking down the silos that have historically prevented comprehensive analysis across imaging and clinical information. (Source: https://developer.nvidia.com/blog/monai-integrates-advanced-agentic-architectures-to-establish-multimodal-medical-ai-ecosystem/)

Why this is pivotal for cancer trial endpoints

Oncology endpoints are multimodal by nature:

  • Radiographic response (RECIST-like measurements on imaging)
  • Pathology markers (histology, tumor grade, sometimes spatial patterns on slides)
  • Labs and vitals (e.g., liver enzymes in hepatotoxicity monitoring)
  • Treatment exposure and adherence (EHR medication administrations)
  • Outcomes (progression-free survival, overall survival)

If your pipeline can’t unify these modalities at the patient and timepoint level, you end up with slow, manual reconciliation—often performed by highly paid clinical staff.

A unified framework enables:

  • Longitudinal patient timelines: synchronizing clinical events with imaging timepoints
  • Site-to-site consistency: standardized preprocessing and model execution
  • Better stratification and subgroup analysis: combining imaging phenotypes with EHR-derived covariates

In practical terms, this is what allows AI to shift from “research prototype” into “trial infrastructure.”

Oncology-ready by design: expert models on demand (including MONAI BraTS)

While public information may not specify exact 2026 cancer trial deployments, MONAI Multimodal provides capabilities that map directly to oncology research needs, including access to specialized expert models on demand, such as MONAI BraTS for brain tumor segmentation. (Source: https://developer.nvidia.com/blog/monai-integrates-advanced-agentic-architectures-to-establish-multimodal-medical-ai-ecosystem/)

Why “expert models on demand” matters for trial portfolios

Many sponsors and academic medical centers run multiple oncology studies simultaneously (glioblastoma, lung, breast, prostate, hematologic malignancies). Each has different imaging endpoints and biomarker requirements.

A key scaling strategy is to standardize the platform and swap task-specific expert models—rather than building separate end-to-end stacks for each study. With expert models available on demand, teams can:

  • Launch segmentation/measurement workflows for specific tumor sites
  • Evaluate imaging biomarkers as exploratory endpoints
  • Compare model outputs across cohorts without rewriting pipelines

Brain tumor segmentation (BraTS) is an especially clear example because volumetrics and enhancement patterns can be highly relevant in neuro-oncology trials.

Digital pathology at enterprise scale: Digital Slide Archive + HistomicsTK and TCGA

Cancer trials are not just radiology-heavy—they’re increasingly pathology-driven. An adjacent, cancer-focused capability highlighted in the ecosystem is that the Digital Slide Archive and HistomicsTK provide an enterprise-grade digital pathology platform for whole-slide imaging (WSI) analysis, supporting large-scale datasets including The Cancer Genome Atlas (TCGA). (Source: https://www.kitware.com/himss-2026/)

Why this matters for 2026 trials

As trials incorporate biomarker stratification and companion diagnostics, WSI analysis becomes more operationally important:

  • Tumor microenvironment features
  • Immune infiltration patterns
  • Morphologic signatures correlated with response or toxicity
  • Quality checks (tumor content, artifact detection)

WSI introduces extreme data scale (gigapixel images) and unique preprocessing challenges. Platforms like Digital Slide Archive + HistomicsTK are designed to handle that enterprise reality, which complements a multimodal ecosystem approach: pathology features can be fused with radiology and EHR-derived covariates to improve patient stratification and endpoint modeling.

Collaborative ecosystem and open-source foundations: avoiding lock-in while supporting real workflows

MONAI Multimodal operates within a collaborative ecosystem involving NVIDIA, premier research institutions, healthcare organizations, and academic centers, supporting research innovation and clinical translation through unified tools for multimodal analysis. (Source: https://developer.nvidia.com/blog/monai-integrates-advanced-agentic-architectures-to-establish-multimodal-medical-ai-ecosystem/)

Just as important, the broader ecosystem emphasizes open-source foundations that help avoid proprietary lock-in while supporting realistic clinical and research workflows. (Source: https://www.kitware.com/himss-2026/)

Practical implications for trial teams

Open and collaborative ecosystems are especially valuable in clinical research because:

  • Trials are multi-site and multi-vendor by nature
  • Methods must be explainable, auditable, and repeatable
  • Tooling must evolve without forcing re-platforming mid-study
  • Data governance often requires on-prem or hybrid deployment options

An open foundation doesn’t automatically solve integration challenges, but it reduces long-term risk and improves interoperability—especially when combined with robust workflow automation.

What this means for 2026 cancer trials: five high-impact use cases

Even without trial-specific deployment announcements, the capabilities described above align directly with how leading oncology studies are evolving. Here are five practical, high-impact applications of multimodal EHR + imaging integration.

1) Automated cohort discovery and eligibility pre-screening

  • Use medical LLMs to map protocol criteria to EHR signals (structured labs, diagnoses, meds; unstructured notes)
  • Link to imaging presence/recency requirements
  • Produce ranked candidate lists with evidence traces

Outcome: faster recruitment and fewer manual chart reviews.

2) Imaging endpoint automation and longitudinal tracking

  • Retrieve baseline and follow-up CT/MR series
  • Run segmentation models to quantify lesion burden
  • Compare across timepoints and summarize response patterns

Outcome: consistent imaging measurements and reduced radiology burden.

3) Safety monitoring with context from imaging + labs

  • Detect radiographic signs (e.g., pneumonitis patterns) and correlate with labs/meds (steroids, immunotherapy exposure)
  • Generate alerts for review teams when multimodal thresholds are met

Outcome: earlier detection of adverse events with fewer false positives.

4) Multimodal biomarker discovery (radiology + pathology + EHR)

  • Extract imaging phenotypes
  • Compute pathology-derived features from WSI
  • Adjust for confounders from EHR (age, comorbidities, prior therapies)

Outcome: stronger exploratory endpoints and more publishable findings.

5) Trial reporting and audit readiness

  • Agentic workflows that assemble:
    • What changed on imaging
    • What treatments occurred
    • What notes document clinical status
  • Produce grounded summaries with references back to source data

Outcome: less time spent assembling narratives, more time interpreting results.

Actionable advice: how to operationalize MONAI Multimodal with workflow automation (n8n)

Multimodal AI platforms are powerful, but in trials the hardest parts are often operational: moving data, enforcing consistency, tracking provenance, and notifying humans at the right times. This is where n8n workflows (and workflow orchestration more broadly) can turn a promising multimodal stack into a repeatable trial pipeline.

A reference automation blueprint (high level)

  1. Trigger: new imaging study arrives, or EHR event occurs (e.g., lab threshold, new chemo administration)
  2. Ingest & validate: verify identifiers, time windows, required modalities present
  3. Route tasks: decide which expert model to run (e.g., brain tumor segmentation)
  4. Execute inference: call model services; track versions and parameters
  5. Post-process & store: write measurements/features back into a trial database
  6. Summarize: generate a clinician-friendly report, grounded in source evidence
  7. Human-in-the-loop: route exceptions to radiology/pathology review queues
  8. Audit log: persist lineage, timestamps, model versions, and prompts

n8n excels as an integration layer for connecting systems (EHR exports, imaging stores, data warehouses, notification channels, ticketing, and model endpoints). It also makes it easier to standardize “trial ops” behaviors: retries, alerts, approvals, and compliance logging.

Key implementation tips for tech teams

  • Treat identifiers and timelines as first-class: patient ID mapping, study dates, and protocol windows must be deterministic.
  • Enforce provenance: log model version, preprocessing steps, and input hashes; trials require repeatability.
  • Design for exceptions: missing series, corrupted DICOMs, incomplete notes—automate the happy path but build robust fallbacks.
  • Keep humans in the loop: especially for endpoints and safety signals; automation should accelerate expert review, not bypass it.

Where AI consulting adds leverage: architecture, governance, and production readiness

Most organizations don’t struggle with “getting a model to run.” They struggle with:

  • integrating with clinical systems,
  • meeting governance requirements,
  • scaling to multiple sites and studies,
  • and making outputs trustworthy to clinicians.

This is where an AI consulting team can provide leverage—especially one experienced in multimodal medical AI and workflow automation.

Typical high-value consulting deliverables for a MONAI Multimodal-style program include:

  • Reference architecture for multimodal pipelines (imaging + EHR + pathology)
  • Data contracts and schema strategy for cross-modal linkage
  • Model governance: versioning, validation plans, drift monitoring, audit trails
  • Automation design using n8n workflows for orchestration, alerts, and approvals
  • Security and compliance patterns (least-privilege access, logging, deployment topology)
  • MLOps/LLMOps practices for medical LLM/VLM integration (prompt/version control, grounding, evaluation)

For 2026 cancer trials, teams that invest early in these foundations are far more likely to move from retrospective studies to prospective, trial-integrated workflows.

Practical takeaways for developers, tech leaders, and innovators

  1. Model performance isn’t the bottleneck—data integration is. MONAI Multimodal’s core value is unifying EHRs, clinical notes, and imaging in a reproducible system. (Source: https://developer.nvidia.com/blog/monai-integrates-advanced-agentic-architectures-to-establish-multimodal-medical-ai-ecosystem/)
  2. Agentic workflows are the next step for clinical AI. Multistep reasoning across images and documentation better matches real trial tasks than single-shot predictions. (Source: https://developer.nvidia.com/blog/monai-integrates-advanced-agentic-architectures-to-establish-multimodal-medical-ai-ecosystem/)
  3. Specialized medical LLMs/VLMs reduce friction in cross-modal linkage. Use them to connect radiology findings to structured EHR fields and narrative evidence. (Source: https://developer.nvidia.com/blog/monai-integrates-advanced-agentic-architectures-to-establish-multimodal-medical-ai-ecosystem/)
  4. Don’t ignore pathology scale. Whole-slide imaging platforms like Digital Slide Archive + HistomicsTK support enterprise-grade WSI and large datasets such as TCGA—critical for modern oncology research. (Source: https://www.kitware.com/himss-2026/)
  5. Automate the pipeline, not just the model. Use n8n workflows (or equivalent orchestration) for ingestion, validation, inference routing, reporting, and audit trails.

Ready to build trial-grade multimodal AI? Let’s talk.

If you’re exploring How MONAI Multimodal integrates EHRs and imaging for 2026 cancer trials and want to move from concept to production, we can help. Our team designs and delivers end-to-end AI consulting and workflow automation solutions—combining multimodal model architectures with n8n workflows to orchestrate real clinical and research processes, including governance, observability, and human-in-the-loop review.

Contact us to discuss your trial pipeline goals—whether you need a multimodal reference architecture, an automation blueprint, or a prototype that can be operationalized across sites.}